Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 480.99M |
| Revenue (ttm) | 1.60M |
| Net Income (ttm) | -328.33M |
| Shares Out | 229.04M |
| EPS (ttm) | -1.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,338,756 |
| Open | 2.05 |
| Previous Close | 2.06 |
| Day's Range | 2.02 - 2.11 |
| 52-Week Range | 1.38 - 9.96 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 5.10 (+142.9%) |
| Earnings Date | Aug 8, 2022 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medic... [Read more...]
Financial Performance
In 2021, INO's revenue was $1.77 million, a decrease of -76.05% compared to the previous year's $7.41 million. Losses were -$303.66 million, 82.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for INO stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 142.86% from the latest price.
News
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PLYMOUTH MEETING, Pa. , July 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases...
Why Inovio Pharmaceuticals Stock Topped the Market on Monday
The appointment of a new top executive clearly meets with investor approval.
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PLYMOUTH MEETING, Pa. , June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious disease...
Stock Market Plunge: 2 Stocks to Avoid Right Now
Prudent investors should look elsewhere.
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with ...
INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 + Libtayo ...
Why Inovio Pharmaceuticals Stock Is Rising Today
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher Monday amid increasing monkeypox concerns. A monkeypox outbreak has been reported in at least a dozen countries.
INOVIO to Present at Jefferies 2022 Healthcare Conference
PLYMOUTH MEETING, Pa. , May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases ...
6 Stocks To Watch Amid Monkeypox Outbreak
A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?
Is This Vaccine Stock in Trouble -- or Ready for a Rebound?
Inovio may be at a turning point.
INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus
Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock.
Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on booster
Inovio Pharmaceuticals Inc.'s INO, +5.06% stock tumbled 21.7% in premarket trading on Wednesday, the day after the company said it will discontinue its work on a COVID-19 vaccine and will instead focus ...
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
INOVIO Reports First Quarter 2022 Financial Results and Program Developments
Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health Repor...
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company foc...
INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022
PLYMOUTH MEETING, Pa. , April 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022.
2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?
These two companies have been left in the dust. Is it too late for them?
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma Financing led by Flerie Invest and Dr. Ted Fjällman joins Geneos' Board of ...
2 Beaten-Down Stocks That Aren't Worth the Trouble
Some cheap stocks aren't bargains.
INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference
PLYMOUTH MEETING, Pa., March 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases ...
Could Inovio Win On This 1 Vaccine Detail?
This vaccine laggard suffered a new setback -- but there is one piece of good news.
Why Inovio Stock Tumbled on a Good Day for the Market Wednesday
The company's Q4 results didn't provide a lot of fuel for optimism.